. 2009 Aug 31;10(9):3776–3792. doi: 10.3390/ijms10093776

Table 2.

IC50 of PHSM^pop-upTAT and free DOX for human promyelocytic leukemia drug-resistant HL-60/MX2 (with decreased TopoII level), human promyelocytic leukemia HL-60 (with bcl-2), human lung drug-resistant NCI-H69/AR (with MRP), and human ovarian tumor A549 (with LRP) cells (n=9). All experiments were performed at pH 6.8 RPMI-1640/PBS medium. IC50 was obtained from the DOX concentration where 50% cell viability was achieved. Reproduced with permission from reference [73].

	PHSM^pop-upTAT	Free DOX
HL-60/MX2 ^a	0.32 ± 0.07 μg/mL	1.12 ± 0.08 μg/mL
HL-60 ^b	0.10 ± 0.03 μg/mL	0.42 ± 0.07 μg/mL
NCI-H69/AR ^c	0.20 ± 0.06 μg/mL	0.75 ± 0.08 μg/mL
A549 ^d	0.75 ± 0.08 μg/mL	6.60 ± 0.09 μg/mL

^a:

IC50 after 1-hour incubation with DOX-loaded formulation;

^b:

IC50 after 1-hour incubation with DOX-loaded formulation;

^c:

IC50 after 24-hour incubation with DOX-loaded formulation;

^d:

IC50 after 48-hour incubation with DOX-loaded formulation.